Cryoport, Inc. (NASDAQ: CYRX) is a Industrials company (Integrated Freight & Logistics) with a market capitalization of $1000M. The Maz Rating grades it against the other companies in its sector.
About three months ago (August 17, 2026), Cryoport, Inc. had a Maz Rating of 3.10 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.70), among the strongest in its sector; its weakest was Growth (1.29), among the weakest in its sector. The other factors: Financial Health 2.93 (around the middle of its sector); Valuation 2.53 (valued in line with its sector); Profitability 2.22 (below most of its sector). The current rating is for members: log in to see it.
At $19.74, Cryoport, Inc. trades at 5.2x sales and 2.1x book value. Over the last twelve months it generated about $193M of revenue and a net loss of $45M. It runs a gross margin of 46.9%, an operating margin of -20.0% and a net margin of -20.9%. It shows return on equity of -8.2%, return on invested capital of -5.4% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 0.48 and a current ratio of 2.04. Over the past 52 weeks the share price ranged from $7.61 to $21.78, with a beta of 1.89.
Cryoport, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 15 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cryoport, Inc. (CYRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 21.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 45.2% / 30% · Interest income / Revenue 6.03% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 21.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 45.2% / 33% · Receivables / Mkt Cap (36m) 4.14% / 49% · Interest income / Revenue 6.03% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 21.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 45.2% / 33.33% · Receivables / Mkt Cap (24m) 4.14% / 33.33% · Interest income / Revenue 6.03% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 24.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 52.9% / 33.33% · Receivables / Avg Assets (4Q) 4.77% / 33.33% · Interest income / Revenue 6.03% / 5% | Fail |
| FTSE | Debt / Total Assets 24.9% / 33.33% · (Cash+ST Inv) / Total Assets 52.3% / 33.33% · (Cash+Recv) / Total Assets 57.1% / 33.33% · Interest income / Revenue 6.03% / 5% | Fail |
No. As of September 2026, Cryoport, Inc. (CYRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cryoport, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 6.03% of each dividend: Cryoport, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.